Which company develops and produces Lynparib/Olaparib? Brand and global supply analysis

Olaparib is a PARP inhibitor developed by AstraZeneca, specifically used to treat cancers related to BRCA gene mutations. The drug was first approved by the US FDA in 2014 and is marketed globally under the brand name Lynparza. In order to promote Lynparza more widely, AstraZeneca has established a partnership with Merck & Co., Inc., in which AstraZeneca is responsible for sales in Europe and other international markets, while Merck & Co., Inc. is mainly responsible for the North American market.

Lynparza is the first PARP inhibitor approved for ovarian cancer, breast cancer, pancreatic cancer and prostate cancer, and has demonstrated superior efficacy in multiple clinical trials. Its main mechanism of action is to selectively kill cancer cells carrying BRCA mutations by inhibiting the DNA repair function of PARP protein. Due to its unique mechanism of action, this drug is widely used in patients with chemotherapy failure or recurrence, and occupies an important position in cancer maintenance treatment.

In terms of global supply, olaparib has been approved in the United States, Europe, China, Japan, Australia and many South American countries, and is one of the most widely used PARP inhibitors on the market. AstraZeneca and Merck jointly promote the global supply chain, making it widely used in the medical systems of many countries, and has been included in the coverage of medical insurance or commercial insurance in some countries. In addition, the drug currently comes in two dosage forms: capsules (50mg) and tablets (100mg, 150mg), with tablets gradually replacing capsules to reduce the number of daily medication doses and improve patient compliance.

As olaparib's indications in multiple cancer areas continue to expand, its market demand continues to grow. AstraZeneca and Merck are accelerating production and supply and ensuring global accessibility of medicines by cooperating with local pharmaceutical companies and setting up production bases.

Reference materials:https://www.lynparza.com/